Evolution of end points for cancer immunotherapy trials (Q50916927)

From Wikidata

Jump to navigation Jump to search

scientific article published in September 2012

edit

Language	Label	Description	Also known as
English	Evolution of end points for cancer immunotherapy trials	scientific article published in September 2012

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

title

Evolution of end points for cancer immunotherapy trials (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

main subject

immunotherapy

1 reference

based on heuristic

inferred from title

author name string

A Hoos

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

publication date

1 September 2012

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

published in

Annals of Oncology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

volume

23 Suppl 8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

page(s)

viii47-52

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

cites work

Improving the efficacy of cancer immunotherapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Cancer immunotherapy: moving beyond current vaccines

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Improved Endpoints for Cancer Immunotherapy Trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Monitoring immune responses in cancer patients receiving tumor vaccines

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

"MIATA"-minimal information about T cell assays

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Validation overview of bio-analytical methods

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

A clinical development paradigm for cancer vaccines and related biologics

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

A methodological framework to enhance the clinical success of cancer immunotherapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS263

retrieved

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS263

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

PubMed publication ID

22918928

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22918928

retrieved

25 March 2018

reference URL

http://europepmc.org/abstract/MED/22918928

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50916927&oldid=2263235448"